Clinical Trial

Tirzepatide for Alcohol Use Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-24; most recent amendment 2025-10-08.
Status change: Not Yet Recruiting → Recruiting 2025-10-08
Trial Details
NCT Number NCT06994338
Lead Sponsor University of Southern California
Collaborators: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions Alcohol Use Disorder, Obesity and Overweight, Alcohol
Enrollment 42 participants
Start Date 2025-10-06
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-10-14